Search

Displaying results 7231 - 7240 of 10000 in total
  1. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. … Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.

  2. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. … While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis

  3. Drug

    AVI-4020

    go.drugbank.com/drugs/DB05873
    Investigational

    AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

  4. Drug

    Astaxanthin

    go.drugbank.com/drugs/DB06543
    Investigational

    Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. … It may be found in fish feed or some animal food as a color additive.

  5. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in

  6. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).

  7. Drug

    Fluprednidene

    go.drugbank.com/drugs/DB08970
    Experimental

    Fluprednidene is a corticosteroid.

    Categories: Corticosteroids, Moderately Potent (Group II)
  8. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. … [L12891] An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia.

  9. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  10. Drug

    Eprinomectin

    go.drugbank.com/drugs/DB11405
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting